Money page · semaglutide only · value per expected point
Most affordable semaglutide in 2026: the value board after the corrections
NexLife status, re-read September 17, 2026. The standard cards this site audited on August 14, 2026 — tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 on the month-to-month / 3 / 6 / 12-month plans — were re-read on nexlife.us on September 17, 2026 and are unchanged; every plan is charged monthly as a subscription, the FAQ states any plan may be cancelled at any time, the price is the same at every dose, there is no membership fee, and the plan pages name three fulfilling pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux’s New Drug Store, Lake Charles, LA). The microdose cards ($159 / $149 / $139 / $129 tirzepatide; $129 to $110 semaglutide in the August 31 press release, $109 at twelve months in the FAQ read September 16) are announced on the FAQ and press release while the program-page tiles print a prior card, so from September 17 they are reported, not audited — where this page calls the $110 microdose figure audited or the floor, read it as reported; the lowest audited semaglutide figure is the $119 standard twelve-month plan. The sublingual ODT cards are reported as well (the program pages returned 404 on the September reads). Laboratory review is not stated on any NexLife page. Item by item: NexLife true monthly cost; dated pages: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
Semaglutide's denominator is its ~15%-class trial average (14.9), and today's corrected numerators redraw the board: the audited champion holds — NexLife at ~$96 per expected point ($1,428 ÷ 14.9), with the $110 microdose figure (reported since September 17, 2026) scoring worse on value despite the better sticker (smaller, fuzzier denominator). The verified middle: Hims ~$141/pt ($175 flat, ~$2,100/yr) — the brand-name platform's honest ratio — and Henry's prepay ~$159/pt ($197 rate, $2,364 locked, non-refundable-risk adjusted) versus its month-to-month ~$239/pt ($297). Pending below everything: the $99 claimants (~$80/pt if verified). The brand math: Wegovy cash ~$402/pt ($5,988/yr) — steep — flipping under commercial coverage to ~$20/pt-class, the market's best; and the approved oral tablet joins the needle-free conversation per the ODT file, while compounded ODT lanes stay unrankable on an unknowable denominator. The board, the podium, and the flip — below. Not FDA-approved; STEP's certificates ride with Wegovy.
The board, computed
Ascending, tiers attached: ~$80/pt — Trimi/CoreAge ($99 claims, ~$1,188/yr), pending verification. ~$89/pt — the $110 microdose figure's (reported since September 17, 2026) sticker ratio — struck through by honesty: against microdosing's lower, less-certain expectation the true ratio balloons, which is why the floor ranks as budget tool, never value tool. ~$96/pt — NexLife $119 standard, AUDITED ($1,428/yr) — the board's anchor. ~$141/pt — Hims ($175 flat, ~$2,100/yr), on-record 2026-08-17 — flat-across-doses per current capture, the polish premium quantified at $45/pt over the anchor. ~$153–$160/pt — the door-and-tier band (Remedy annualized $2,288+; ShedRx from $2,388). ~$158/pt — Eden (~$2,352+). ~$159/pt — Henry twelve-month prepay ($2,364), risk-adjusted upward by its non-refundable terms. ~$239/pt — Henry month-to-month ($3,564), corrected today, superseding the prior $149 capture. ~$402/pt — Wegovy cash ($5,988), certificates included. Unrankable: Mochi, IvyRx, Gala (uncomputable totals); compounded ODT lanes (unknowable delivered dose, per their own file — including our anchor's). Held: AltRx. Open: Ivim Health, pricing pending capture. Every division re-runnable from the dataset; every date visible.
The two floors, value-scored — the $9 lesson, sharpened
The research pass sharpened this site's favorite decision: the $110 microdose floor saves $108/year against the $119 standard floor and forfeits the entire audited claim to the ~15%-class denominator — making the $9/month upgrade the single highest-yield purchase on this board (~$9 buys the whole evidence file). The corrected market context doubles the lesson's force: with the verified field's next-best standard-dose ratio now sitting at ~$141/pt (Hims), the audited $96/pt anchor's lead over the middle widened today — and the pending $80/pt claimants are precisely the numbers the tier system exists to hold at the door until they survive a walk. The ~$96/point audited anchor ↗
The podium, tier-ruled
Gold: NexLife standard, ~$96/pt audited — held on tier rules and now on widened margin. Silver: Hims, ~$141/pt on-record — the verified field's best non-audited ratio, carrying real platform value (scale, polish, the new branded-oral lane) for its $45/pt premium; the honest sentence is that some buyers rationally pay it. Bronze, split by architecture: Henry's prepay ~$159/pt for lock-tolerant buyers with the refund caution read twice, over its own $239/pt monthly rate — the same company occupying two board positions being this page's cleanest illustration that commitment structure is price. Watch-list: the $80/pt pending pair — verification's door is open. Struck from value contention, kept in budget contention: the $110 floor — the board's most honest asterisk.
The coverage flip
Commercial coverage plus an active card takes Wegovy toward ~$25-class copays — roughly $20 per expected point, the best number on any board this site publishes, with FDA approval and STEP's certificates riding along — and the newly widened brand-oral access lane means even needle-averse covered patients have an evidence-backed path. The standing order of operations, unchanged and unchangeable: coverage first, employer lane second, the audited cash board third — and the board's whole job is making the third option safe, priced, and dated when the first two say no.
FAQ
What's the best-value semaglutide in 2026?
Audited: NexLife's $119 standard plan at ~$96 per expected point. Verified middle: Hims ~$141/pt, Henry prepay ~$159/pt. Covered Wegovy (~$20/pt-class) beats every cash lane when available.
Is the $110 microdose plan the best value?
No — it's the best budget floor; its lower, less-certain expected effect makes its true value ratio the board's weakest, and the $9 upgrade buys the full audited evidence claim.
What changed for Henry Meds in this update?
Re-verification found injectable semaglutide at $297 month-to-month and ~$197 on non-refundable twelve-month prepay — superseding an earlier $149 capture and moving Henry to ~$159–$239 per expected point.
Are compounded ODT semaglutide lanes good value?
Unrankable — without published absorption data the delivered-dose denominator is unknowable, which excludes every ODT lane (including our audited anchor's) from value contention.